BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 24933362)

  • 1. FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases.
    Turo R; Harnden P; Thygesen H; Fleischmann A; Thalmann GN; Seiler R; Cross WR; Knowles MA
    J Urol; 2015 Jan; 193(1):325-30. PubMed ID: 24933362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
    Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and location of lymph node metastases in patients undergoing radical cystectomy for clinical non-muscle invasive bladder cancer: results from a prospective lymph node mapping study.
    Bruins HM; Skinner EC; Dorin RP; Ahmadi H; Djaladat H; Miranda G; Cai J; Daneshmand S
    Urol Oncol; 2014 Jan; 32(1):24.e13-9. PubMed ID: 23395238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroblast growth factor receptor 3 protein expression in urothelial carcinoma of the urinary bladder, exhibiting no association with low-grade and/or non-invasive lesions.
    Matsumoto M; Ohtsuki Y; Ochii K; Seike Y; Iseda N; Sasaki T; Okada Y; Kurabayashi A; Furihata M
    Oncol Rep; 2004 Nov; 12(5):967-71. PubMed ID: 15492779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
    van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
    Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clonal origin of lymph node metastases in bladder carcinoma.
    Jones TD; Carr MD; Eble JN; Wang M; Lopez-Beltran A; Cheng L
    Cancer; 2005 Nov; 104(9):1901-10. PubMed ID: 16196038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of proteins FGFR3, PI3K, AKT, p21Waf1/Cip1 and cyclins D1 and D3 in patients with T1 bladder tumours: clinical implications and prognostic significance.
    Blanca Pedregosa AM; Sánchez-González Á; Carrasco Valiente J; Ruiz García JM; Gómez Gómez E; López Beltrán A; Requena Tapia MJ
    Actas Urol Esp; 2017 Apr; 41(3):172-180. PubMed ID: 27726892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphovascular invasion of urothelial cancer in matched transurethral bladder tumor resection and radical cystectomy specimens.
    Kunju LP; You L; Zhang Y; Daignault S; Montie JE; Lee CT
    J Urol; 2008 Nov; 180(5):1928-32; discussion 1932. PubMed ID: 18801529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
    van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
    J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer.
    Jaeger TM; Weidner N; Chew K; Moore DH; Kerschmann RL; Waldman FM; Carroll PR
    J Urol; 1995 Jul; 154(1):69-71. PubMed ID: 7539869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only.
    Steven K; Poulsen AL
    J Urol; 2007 Oct; 178(4 Pt 1):1218-23; discussion 1223-4. PubMed ID: 17698113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential for molecular-targeted therapy targeting human epidermal growth factor receptor-2 for invasive bladder cancer.
    Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Inoue Y; Noguchi H; Honda N
    Oncol Rep; 2007 Jul; 18(1):3-7. PubMed ID: 17549338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors.
    Jimenez RE; Hussain M; Bianco FJ; Vaishampayan U; Tabazcka P; Sakr WA; Pontes JE; Wood DP; Grignon DJ
    Clin Cancer Res; 2001 Aug; 7(8):2440-7. PubMed ID: 11489824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.
    Bodoor K; Ghabkari A; Jaradat Z; Alkhateeb A; Jaradat S; Al-Ghazo MA; Matalka I; Musleh H; Haddad Y
    Cancer Epidemiol; 2010 Dec; 34(6):724-32. PubMed ID: 20542753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The FGFR3 mutation is related to favorable pT1 bladder cancer.
    van Rhijn BW; van der Kwast TH; Liu L; Fleshner NE; Bostrom PJ; Vis AN; Alkhateeb SS; Bangma CH; Jewett MA; Zwarthoff EC; Zlotta AR; Bapat B
    J Urol; 2012 Jan; 187(1):310-4. PubMed ID: 22099989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.
    Mills RD; Turner WH; Fleischmann A; Markwalder R; Thalmann GN; Studer UE
    J Urol; 2001 Jul; 166(1):19-23. PubMed ID: 11435814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.